Potential therapeutic strategy for non-Hodgkin lymphoma by anti-CD20scFvFc/CD28/CD3zeta gene tranfected T cells.

about

Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China.Inhibition of p38 MAPK activity in B-NHL Raji cells by treatment with engineered CD20-specific T cells.

P2860

Q38786626-F0C83824-3185-4B30-82DD-AD688B259086 Q39305171-CC3559C5-0BC2-43C2-8398-C91C2B9886D8

P2860

Potential therapeutic strategy for non-Hodgkin lymphoma by anti-CD20scFvFc/CD28/CD3zeta gene tranfected T cells.

Item

http://www.wikidata.org/entity/Q39659837

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Potential therapeutic strategy ...... 3zeta gene tranfected T cells.

@en

Potential therapeutic strategy ...... 3zeta gene tranfected T cells.

@nl

type

Item

label

Potential therapeutic strategy ...... 3zeta gene tranfected T cells.

@en

Potential therapeutic strategy ...... 3zeta gene tranfected T cells.

@nl

prefLabel

Potential therapeutic strategy ...... 3zeta gene tranfected T cells.

@en

Potential therapeutic strategy ...... 3zeta gene tranfected T cells.

@nl

P1476

Potential therapeutic strategy ...... 3zeta gene tranfected T cells.

@en

P2093

Jimei Du

http://www.w3.org/2001/XMLSchema#string

Kang Yu

http://www.w3.org/2001/XMLSchema#string

Lei Jiang

http://www.w3.org/2001/XMLSchema#string

Panpan Yu

http://www.w3.org/2001/XMLSchema#string

Shenghui Zhang

http://www.w3.org/2001/XMLSchema#string

Yihu Zheng

http://www.w3.org/2001/XMLSchema#string

Yingxia Tan

http://www.w3.org/2001/XMLSchema#string

Yixiang Han

http://www.w3.org/2001/XMLSchema#string

P2860

Stromal gene signatures in large-B-cell lymphomas

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28

Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.

Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.

Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes.

Treatment of lymphoma with adoptively transferred T cells.

CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin's lymphoma.

Immunotherapy of lymphomas with T cells modified by anti-CD20 scFv/CD28/CD3zeta recombinant gene.

Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma.

P2888

1756-9966-29-121

P304

121

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1756-9966-29-121

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2010-09-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46147257

http://www.w3.org/2001/XMLSchema#string

P6179

1047537725

http://www.w3.org/2001/XMLSchema#string

P698

20815894

http://www.w3.org/2001/XMLSchema#string

P932

2939546

http://www.w3.org/2001/XMLSchema#string

Potential therapeutic strategy for non-Hodgkin lymphoma by anti-CD20scFvFc/CD28/CD3zeta gene tranfected T cells.

about

P2860

P2860

Potential therapeutic strategy for non-Hodgkin lymphoma by anti-CD20scFvFc/CD28/CD3zeta gene tranfected T cells.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P577

P5875

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P577

P5875

P6179

P698

P932